<?xml version="1.0" encoding="UTF-8"?>
<p>The implementation of the revised pharmacovigilance legislation in 2012 has offered robust regulatory instruments and has established clear roles and responsibilities to directly manage most safety issues without the need to go through the IRN mechanism. In so doing, it has reduced the number of ad‚Äêhoc IRN meetings needed, thus making use of the already existing regulatory options and increasing the overall efficiency of the Network.</p>
